Industria farmacéutica

Compartamos los cuidados con el mundo

Mejora el acceso, el rendimiento y la responsabilidad con una logística especializada para la industria farmacéutica y sanitaria.

Contáctanos

Reducing GHG emissions in global logistics with Novo Nordisk

Discover how Novo Nordisk, together with Maersk, is transforming supply chains to lower greenhouse gas (GHG) emissions. Watch the video to learn about our efforts and ongoing journey towards decarbonisation in logistics.

02:26
sustainability shift

Why temperature control and intervention is a life-saver for pharmaceutical cargo

Temperature control and timely intervention are critical to ensure the integrity of pharmaceutical cargo. Even slight deviations can compromise the quality of life-saving medicines, disrupt their movement, and set companies back. For a deep-dive into the strategies and technologies that safeguard these vital shipments, read an insightful article by our pharma specialist Sebastian Steinmueller.
Learn more
female-worker-holding-box

AI and Pharma: the next best duo

Considering how artificial intelligence is already revolutionising all industries, how can AI change the pharmaceutical industry and its supply chains? What are the benefits and challenges? Explore the 7 ways artificial intelligence can boost the pharmaceutical industry in this research piece.
Learn more
Macro photography of glasses on tray

The importance of visibility for pharma supply chains

Time and quality control are key for pharma supply chains given the particularity of their cargo, but what role does visibility play? What exactly does visibility mean for pharma supply chains? In this research piece, see how better data can help visibility and what the future holds.
Learn more
Medical professionals in safety suits working in a pharmaceutical laboratory

The ever-evolving cold chain needs of the pharma industry

Healthcare expenditure in the European Union is projected to surge to a staggering 350% by 2050. This seismic shift is reshaping the pharmaceutical landscape, propelling global cold chain investments to an anticipated 21.3 billion USD. But how are companies adapting? Join us as we uncover the transformative impact of market innovations on pharmaceutical logistics, guided by insights from Gaëtan Van Exem, Global Vertical Head of Pharma and Healthcare. 
Read the article

How a global pharma company reduced their GHG emissions 

By choosing Maersk ECO Delivery Ocean, this pharma company was able to get closer to their decarbonisation goals while still delivering essential care all around the world. 
Read case study
Maersk ship

Transforming pharma supply chains for the future 

Read our latest article by Gaetan Van Exem, Global Vertical Head, Pharma and Healthcare Cold Chain Vertical which explains the vital role of trusted partnerships and truly integrated logistics in building reliable and resilient pharma cold chain solutions. 
Read the article
Ship yard

The great Indian pharma story

India is a global pharmaceutical powerhouse, on course to being a $450 billion industry by 2047. The country contributes to over 20% of the world's drug supply chain and manufactures over 60% of the global demand for vaccines. What makes the pharma industry tick in India? How are the latest innovations in technology changing the face of how the sector is run and the medicines transported? What supply chain challenges does it encounter?
Read our article for a comprehensive understanding of the latest developments and challenges in the Indian pharma industry.
Read now

Gestionar, conectar, simplificar

Las principales empresas farmacéuticas y sanitarias del mundo confían en Maersk para entregar sus productos de forma segura en cualquier parte del mundo. Gracias a nuestra profunda experiencia, al cumplimiento de las normas GDP, a las soluciones integrales de la cadena de frío, a los equipos de última generación y al compromiso de larga duración con la sostenibilidad, somos tu socio para la logística farmacéutica. Sigue la cadena de suministro farmacéutica en nuestra infografía para ver cómo llegamos hasta el final.
VER INFOGRAFÍA
Infografía

Conectando las cadenas de suministro de forma novedosa para el sector farmacéutico y sanitario

Dentro de veinte años, cuando echemos la vista atrás para ver la evolución de las cadenas de suministro mundiales, veremos dos periodos muy distintos: antes y después de COVID-19. Sí, ha habido virus antes, pero ninguno en nuestro mundo moderno y globalizado, donde el comercio transfronterizo representa el 50 % del PIB. Nunca hemos tenido una cadena de suministro que contenga tantas partes en movimiento a través de tantos países con tantas partes interesadas. Y esa cadena de suministro nunca se ha visto sometida a la presión de los últimos tiempos, a no ser que se cuente con los ejercicios teóricos o los planes para catástrofes de académicos y gestores de riesgos.

En ámbitos como el farmacéutico y el sanitario, los profesionales están equilibrando esta necesidad de respuesta reactiva con el diseño de un futuro más confiable, transparente e inteligente para sus cadenas de suministro. Para lograr el cambio, estas empresas tienen que evaluar toda la cadena, desde la fabricación hasta la entrega, pasando por las aduanas, el almacenamiento y el cliente final.

En este eBook evaluamos las últimas innovaciones y evoluciones y valoramos cómo podría ser el futuro de la logística farmacéutica y sanitaria en su conjunto. Destacamos algunas de las áreas clave en las que Maersk está impulsando la innovación integral mediante la evolución de los procesos, la tecnología y la colaboración.

MÁS INFORMACIÓN
Conectando las cadenas de suministro de forma novedosa para el sector farmacéutico y sanitario

Re-evaluating the modal mix for pharmaceutical supply chains

Transporting the most fragile, high-value, regulated cargo in the world is complex. Even more so when you need to roll out billions of doses of a vaccine across continents to every person on the planet. Add to that the pressures of running a supply chain focused on reducing greenhouse gas (GHG) emissions, and pharma companies could find themselves in a dilemma. Unless they add a healthy dose of shipping to their modal mix. It’s reliable, makes essential products accessible to patients around the globe, and emits less GHG emissions than most other modes of transportation, such as air transportation.
Re-evaluating the modal mix for pharmaceutical supply chains